These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8654651)

  • 1. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women.
    Cicinelli E; Borraccino V; Petruzzi D; Mazzotta N; Cerundolo ML; Schönauer LM
    Fertil Steril; 1996 Apr; 65(4):860-2. PubMed ID: 8654651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study.
    Miles RA; Paulson RJ; Lobo RA; Press MF; Dahmoush L; Sauer MV
    Fertil Steril; 1994 Sep; 62(3):485-90. PubMed ID: 8062942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension.
    Vilodre LC; Osório Wender MC; Sisson de Castro JA; dos Reis FM; Ruschel S; Magalhães JA; Spritzer PM
    Gynecol Endocrinol; 2003 Aug; 17(4):323-8. PubMed ID: 14503977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of micronized progesterone on the endometrium: a systematic review.
    Stute P; Neulen J; Wildt L
    Climacteric; 2016 Aug; 19(4):316-28. PubMed ID: 27277331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert.
    Paulson RJ; Collins MG; Yankov VI
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4241-9. PubMed ID: 24606090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study.
    Cicinelli E; de Ziegler D; Alfonso R; Nicoletti R; Bellavia M; Colafiglio G
    Fertil Steril; 2005 Jun; 83(6):1859-63. PubMed ID: 15950667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women.
    Pasquale SA; Foldesy RG; Levine JP; Bachmann GA; Blackwell RE
    Fertil Steril; 1997 Nov; 68(5):810-5. PubMed ID: 9389807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo.
    Duijkers IJM; Klingmann I; Prinz R; Wargenau M; Hrafnsdottir S; Magnusdottir TB; Klipping C
    Hum Reprod; 2018 Nov; 33(11):2131-2140. PubMed ID: 30265306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High local endometrial effect of vaginal progesterone gel.
    Ficicioglu C; Gurbuz B; Tasdemir S; Yalti S; Canova H
    Gynecol Endocrinol; 2004 May; 18(5):240-3. PubMed ID: 15346659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study.
    Cicinelli E; de Ziegler D; Galantino P; Pinto V; Barba B; Morgese S; Schonauer S
    Am J Obstet Gynecol; 2002 Sep; 187(3):556-60. PubMed ID: 12237627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women.
    Cicinelli E; Cignarelli M; Sabatelli S; Romano F; Schonauer LM; Padovano R; Einer-Jensen N
    Fertil Steril; 1998 Mar; 69(3):471-3. PubMed ID: 9531879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial.
    Casanova G; Spritzer PM
    Lipids Health Dis; 2012 Oct; 11():133. PubMed ID: 23046709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the repetitive administration of progesterone by nasal spray in postmenopausal women.
    Cicinelli E; Cignarelli M; Resta L; Scorcia P; Petruzzi D; Santoro G
    Fertil Steril; 1993 Dec; 60(6):1020-4. PubMed ID: 8243679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol.
    Fernández-Murga L; Hermenegildo C; Tarín JJ; García-Pérez MÁ; Cano A
    Climacteric; 2012 Oct; 15(5):455-9. PubMed ID: 22321028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women.
    Sriprasert I; Mert M; Mack WJ; Hodis HN; Shoupe D
    Maturitas; 2021 Dec; 154():13-19. PubMed ID: 34736575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and pharmacodynamics of two 10-mg estradiol valerate depot formulations following IM single dose administration in healthy postmenopausal volunteers.
    Schug BS; Donath F; Blume HH
    Int J Clin Pharmacol Ther; 2012 Feb; 50(2):100-17. PubMed ID: 22257576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.